Genomic Tumour Profiling

Genomic tumour profiling examines changes in cancer-cell DNA to help your oncology team consider treatment options.

Also called molecular profiling or tumour sequencing, it looks at a sample from the tumour rather than testing every aspect of your health. Cancer cells can acquire DNA changes as they grow. Finding certain changes may help the team match treatment discussions to the biology of that particular cancer.

The laboratory usually uses tissue already collected during diagnosis or surgery. A pathologist checks whether the sample has enough tumour cells and suitable material. The laboratory then extracts genetic material and analyses selected genes or a broader panel. Some situations call for a newly collected tissue sample or a blood sample; your team explains why a particular sample is being considered.

Testing stored tumour material does not add a physical procedure. If a fresh sample is needed, any discomfort or complications come from the sampling procedure, not from the laboratory analysis. A result can be limited by the amount or quality of tumour material, and different parts of a tumour may not carry identical changes. A detected change is a reliable laboratory finding when the sample is adequate, but it does not always identify a treatment that is appropriate or available for you.

In this setting, a result may report a genomic alteration rather than label it as simply normal or abnormal. Your oncologist considers whether that alteration is relevant to the cancer type, its current stage, treatments already received and your overall health. The discussion may lead to targeted therapy, another systemic treatment, further testing, or a plan to continue the treatment already chosen. Some changes have no current treatment implication.

Tumour profiling is one part of treatment planning. It is interpreted alongside the pathology report, scan findings and your clinical history. It is different from inherited genetic testing, which looks for changes that can run in families. Tell the team if you have been offered genetic counselling or have a notable family history, because a tumour result can sometimes prompt a separate conversation about inherited testing.

An oncology team may consider profiling when a cancer has returned, has spread, is unusual to classify, or when treatment decisions could be shaped by a tumour feature. It may be discussed in breast, bowel, lung and ovarian cancers, among others. It can also be useful when the original site of a cancer cannot be identified. Being offered the test does not mean a particular result or treatment will follow.

Your clinician requests the test and identifies the most suitable available sample. The laboratory prepares the material, performs the analysis and issues a report for the cancer team. Your oncologist then puts the findings into context with the rest of your care plan. Bring questions to the results appointment, including what the finding changes, what it does not change and whether any further sample is needed.

There is no recovery period when the laboratory uses an existing specimen. If a new biopsy is arranged, recovery depends on the site and method used to obtain tissue; the treating team provides aftercare instructions. Analysis and report review take time, so your cancer treatment plan may proceed while results are pending when waiting would not be appropriate.

The main limitations are an insufficient sample, a result with unclear significance, or a finding without a suitable treatment option. A report may also fail to detect a change if it is not present in the tested cells or the sample cannot support the analysis. If new tissue is required, discuss the specific risks of that procedure and whether another sample source is possible.

Standard pathology, imaging and other laboratory tests remain central to diagnosis and treatment planning. In some cases, a smaller focused test can answer the immediate clinical question. In others, repeating a biopsy or using a blood-based test may be considered if tissue is unavailable. The choice depends on the cancer type, the clinical question and the material available.

Look for a cancer service where medical oncology, pathology and diagnostic specialists can review results together. Ask whether the laboratory report will be discussed in a multidisciplinary meeting, who will explain the findings to you, and how the result may affect the next treatment decision. Keep a copy of your report and pathology records for future consultations.